Search research articles
Contact Us
Filters
Showing results (141-150 of 148) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 148 results.
Blood Advances
|
December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Blood
|
July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
Youn H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
Vincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
British Journal of Haematology
|
November 9, 2019
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
Catherine Thieblemont, Susannah Howlett, René-Olivier Casasnovas, et al.
Blood Advances
|
February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Blood
|
August 24, 2022
Genomic profiling for clinical decision making in lymphoid neoplasms
Laurence de Leval, Ash A Alizadeh, P Leif Bergsagel, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 148) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 148 results.
Blood Advances
|
December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Blood
|
July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
Youn H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
Vincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
British Journal of Haematology
|
November 9, 2019
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
Catherine Thieblemont, Susannah Howlett, René-Olivier Casasnovas, et al.
Blood Advances
|
February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Blood
|
August 24, 2022
Genomic profiling for clinical decision making in lymphoid neoplasms
Laurence de Leval, Ash A Alizadeh, P Leif Bergsagel, et al.
Page
of 15